CA2921816A1 - Treatment of pediatric otic disorders - Google Patents

Treatment of pediatric otic disorders Download PDF

Info

Publication number
CA2921816A1
CA2921816A1 CA2921816A CA2921816A CA2921816A1 CA 2921816 A1 CA2921816 A1 CA 2921816A1 CA 2921816 A CA2921816 A CA 2921816A CA 2921816 A CA2921816 A CA 2921816A CA 2921816 A1 CA2921816 A1 CA 2921816A1
Authority
CA
Canada
Prior art keywords
composition
ciprofloxacin
middle ear
treatment
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2921816A
Other languages
English (en)
French (fr)
Inventor
Fabrice Piu
Qiang Ye
Luis A. Dellamary
Carl Lebel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otonomy Inc
Original Assignee
Otonomy Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otonomy Inc filed Critical Otonomy Inc
Publication of CA2921816A1 publication Critical patent/CA2921816A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2921816A 2013-08-27 2014-08-26 Treatment of pediatric otic disorders Abandoned CA2921816A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361870318P 2013-08-27 2013-08-27
US61/870,318 2013-08-27
US201361914904P 2013-12-11 2013-12-11
US61/914,904 2013-12-11
PCT/US2014/052754 WO2015031393A1 (en) 2013-08-27 2014-08-26 Treatment of pediatric otic disorders

Publications (1)

Publication Number Publication Date
CA2921816A1 true CA2921816A1 (en) 2015-03-05

Family

ID=52587275

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2921816A Abandoned CA2921816A1 (en) 2013-08-27 2014-08-26 Treatment of pediatric otic disorders

Country Status (10)

Country Link
US (2) US9486405B2 (cg-RX-API-DMAC7.html)
EP (1) EP3038707A4 (cg-RX-API-DMAC7.html)
JP (1) JP2016534121A (cg-RX-API-DMAC7.html)
KR (1) KR20160047490A (cg-RX-API-DMAC7.html)
CN (1) CN105682742A (cg-RX-API-DMAC7.html)
AU (1) AU2014311358A1 (cg-RX-API-DMAC7.html)
CA (1) CA2921816A1 (cg-RX-API-DMAC7.html)
EA (1) EA201690323A1 (cg-RX-API-DMAC7.html)
MX (1) MX2016002408A (cg-RX-API-DMAC7.html)
WO (1) WO2015031393A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
CN106794144B (zh) * 2014-07-03 2020-07-17 奥德纳米有限公司 环丙沙星组合物的灭菌
EP3028721A1 (en) * 2014-12-05 2016-06-08 Exchange Imaging Technologies GmbH Nanoparticle formulation having reverse-thermal gelation properties for injection
EP3512513A4 (en) 2016-09-16 2020-04-15 Otonomy, Inc. OTIC GEL FORMULATIONS FOR THE TREATMENT OF EXTERNAL OTITIS
US20180092911A1 (en) * 2016-09-30 2018-04-05 Otonomy, Inc. Otic gel formulations for treating otitis media
WO2019140012A1 (en) 2018-01-09 2019-07-18 Otonomy, Inc. Growth factor otic formulations
US10561736B1 (en) 2019-01-09 2020-02-18 Spiral Therapeutics, Inc. Apoptosis inhibitor formulations for prevention of hearing loss
EP3962533A4 (en) 2019-04-30 2023-01-25 The Medical College of Wisconsin, Inc. PLATFORM FOR THROAT ADMINISTRATION AND USES THEREOF
TWI781536B (zh) 2021-02-26 2022-10-21 國立臺灣科技大學 藥物釋放組合物、其製造方法及其用途

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4188373A (en) 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4478822A (en) 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4968507A (en) 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
JPH01258620A (ja) 1988-04-08 1989-10-16 Dai Ichi Seiyaku Co Ltd 耳疾患用局所製剤
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5292516A (en) 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
IT1251151B (it) 1991-08-05 1995-05-04 Fidia Spa Materiale spugnoso essenzialmente costituito da acido ialuronico,o suoi derivati
EP0551626A1 (en) 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
JP3696265B2 (ja) 1994-02-04 2005-09-14 日本オルガノン株式会社 点鼻液剤
EP1125577B1 (en) 1994-04-08 2006-02-15 QLT USA, Inc. Liquid drug delivery compositions
WO1997005185A2 (en) 1995-07-28 1997-02-13 Focal, Inc. Multiblock biodegradable hydrogels for use as controlled release agents for drugs delivery and tissue treatment agents
AU2676397A (en) 1996-04-18 1997-11-07 University Technology Corporation Methods for treating middle and inner ear disorders
US5861174A (en) 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
US6045528A (en) 1997-06-13 2000-04-04 Intraear, Inc. Inner ear fluid transfer and diagnostic system
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
KR20010031363A (ko) 1997-10-22 2001-04-16 젠스 포니카우 진균류에 의한 점막염을 국소 치료하기 위한 항진균제의용도
DE19748763A1 (de) 1997-11-05 1999-05-06 Hans Peter Zenner Verwendung von Vasopressin-Antagonisten
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6649621B2 (en) 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6177434B1 (en) 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
JP2001526246A (ja) 1997-12-23 2001-12-18 アライアンス・ファーマスーティカル・コーポレイション 薬剤送達及び/又は癒着防止のための方法及び組成物
WO2000007603A2 (en) 1998-08-04 2000-02-17 Madash Llp End modified thermal responsive hydrogels
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6740664B2 (en) 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
EP1158957A4 (en) 1999-02-24 2004-12-15 Dong Wha Pharm Ind Co Ltd LIQUID SUPPOSITORIAL COMPOSITION OF DICLOFENAC SODIUM
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
DE60006262T2 (de) 1999-09-24 2004-05-13 Alcon, Inc. Topische suspensionsformulierungen enthaltend ciprofloxacin und dexamethason
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
AU4741001A (en) 2000-03-14 2001-09-24 Alcon Universal Ltd Viscoelastics for use in middle ear surgery
US6998137B2 (en) 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
US7758888B2 (en) 2000-04-21 2010-07-20 Sol-Gel Technologies Ltd. Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US7018645B1 (en) 2000-04-27 2006-03-28 Macromed, Inc. Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
SE0100158D0 (sv) 2001-01-19 2001-01-19 Synphora Ab Novel method and composition for local treatment of Meniere´s disease and tinnitus
US20060269602A1 (en) 2001-04-13 2006-11-30 Dasch James R Method of modifying the release profile of sustained release compositions
US20040022853A1 (en) 2001-04-26 2004-02-05 Control Delivery Systems, Inc. Polymer-based, sustained release drug delivery system
TWI324925B (en) 2001-08-23 2010-05-21 Novartis Ag Ophthalmic composition
US6488952B1 (en) 2001-08-28 2002-12-03 John P. Kennedy Semisolid therapeutic delivery system and combination semisolid, multiparticulate, therapeutic delivery system
US20030139382A1 (en) * 2001-09-21 2003-07-24 Alcon, Inc. Method of treating middle ear infections
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
DE10162593A1 (de) 2001-12-19 2003-07-03 Menarini Ricerche Spa Stabilisierte topische Brivudin-Formulierungen
US20030229333A1 (en) 2002-02-22 2003-12-11 Control Delivery Systems, Inc. Methods for treating otic disorders
US20060013858A1 (en) 2002-10-29 2006-01-19 Trune Dennis R Fludrocortisone treatment for hearing loss
US20040101506A1 (en) 2002-11-25 2004-05-27 Fust Charles A. Composition for the prevention and treatment of inflammation of the ear
US7220431B2 (en) 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
US20040204471A1 (en) 2003-03-20 2004-10-14 Pharmacia Corporation Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents
US7700086B2 (en) 2003-11-06 2010-04-20 Pluromed, Inc. Internal clamp for surgical procedures
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
WO2005115527A2 (en) 2004-05-24 2005-12-08 Auris Medical, Llc. Combined otic aspirator and medication dispenser
US7858115B2 (en) 2004-06-24 2010-12-28 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US20060034889A1 (en) 2004-08-16 2006-02-16 Macromed, Inc. Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof
US20060046970A1 (en) 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
US20080124385A1 (en) 2004-09-03 2008-05-29 Piedmont Pharmaceuticals,Llc. Methods for Transmembrane Treatment and Prevention of Otitis Media
JP2006111585A (ja) 2004-10-15 2006-04-27 Mebiol Kk 徐放性組成物およびその徐放方法
JP2008537684A (ja) 2005-01-24 2008-09-25 ニューロシステック コーポレイション 内耳およびその他の組織へ治療薬および/またはその他の薬剤を送達するための装置および方法
TW200719884A (en) 2005-03-10 2007-06-01 3M Innovative Properties Co Methods of treating ear infections
CA2600282A1 (en) 2005-03-29 2006-10-05 Roehm Gmbh Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release
EP1893174A2 (en) 2005-05-10 2008-03-05 Cytophil, Inc. Injectable hydrogels and methods of making and using same
KR101041843B1 (ko) 2005-07-30 2011-06-17 삼성엘이디 주식회사 질화물계 화합물 반도체 발광소자 및 그 제조방법
US20070048338A1 (en) 2005-08-26 2007-03-01 Ladd Byron S Compositions and methods for surface treatment in medical and surgical procedures
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
CN101272807A (zh) 2005-09-26 2008-09-24 皮埃蒙特医药品有限公司 使用非离子表面活性剂促进跨膜药物输送到中耳治疗和预防中耳炎的方法
EP1928439A4 (en) 2005-09-26 2009-04-29 Piedmont Pharmaceuticals Llc METHOD FOR THE TREATMENT AND PREVENTION OF OTITIS MEDIA WITH CHEMICAL PENETRATION AMPLIFIERS TO FACILITATE THE TRANSMEMBRANOESE DRUG DELIVERY IN THE MIDDLE EAR
CA2620374C (en) 2005-09-28 2012-12-11 Thomas Meyer Pharmaceutical compositions for the treatment of inner ear disorders
US20070110788A1 (en) 2005-11-14 2007-05-17 Hissong James B Injectable formulation capable of forming a drug-releasing device
US20070178051A1 (en) 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
CA2655596C (en) 2006-06-27 2011-10-25 Biovail Laboratories International Srl Multiparticulate osmotic delivery system
WO2008076556A2 (en) 2006-11-15 2008-06-26 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
JP2010512230A (ja) 2006-12-11 2010-04-22 プルーロームド インコーポレイテッド 灌流臓器止血法
JP2010525073A (ja) 2007-04-23 2010-07-22 ハウス イアー インスティトゥート 代謝型グルタミン酸受容体7の調節による老人性難聴の治療及び/又は予防
US7795231B2 (en) 2007-10-04 2010-09-14 Insite Vision Incorporated Concentrated aqueous azalide formulations
WO2009132050A2 (en) 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
MY161021A (en) 2008-05-14 2017-03-31 Otonomy Inc Controlled release corticosteroid and methods for the treatment of otic disorders
WO2009142719A2 (en) * 2008-05-19 2009-11-26 Massachusetts Institute Of Technology Tympanic membrane permeating ear drops and uses thereof
US8648119B2 (en) 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
US8846770B2 (en) 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
US8349353B2 (en) 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
WO2010011466A2 (en) 2008-06-27 2010-01-28 Otonomy, Inc. Controlled-release cns modulating compositions and methods for the treatment of otic disorders
EP2296632A4 (en) 2008-07-14 2014-11-12 Otonomy Inc COMPOSITIONS AND METHODS FOR MODULATING CONTROLLED RELEASE APOPTOSIS FOR THE TREATMENT OF OTIC DISORDERS
WO2010011605A2 (en) 2008-07-21 2010-01-28 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
MX2011000862A (es) * 2008-07-21 2011-03-15 Otonomy Inc Composiciones antimicrobianas de liberacion controlada y metodos para el tratamiento de trastornos oticos.
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8399018B2 (en) 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US20100016450A1 (en) 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
CN101664381A (zh) 2009-08-21 2010-03-10 天津生机集团股份有限公司 治疗奶牛乳房炎的原位凝胶缓释制剂的制备方法
JP2013508381A (ja) * 2009-10-21 2013-03-07 オトノミ―,インク. ポロクサマーを包含する製剤のゲル化温度の調節
WO2011049958A2 (en) 2009-10-21 2011-04-28 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations
ES2369101B2 (es) 2010-05-07 2012-08-02 Universidade De Santiago De Compostela Sistema farmacéutico acuoso para la administración de fármacos en las uñas.

Also Published As

Publication number Publication date
MX2016002408A (es) 2016-10-28
US9486405B2 (en) 2016-11-08
EP3038707A1 (en) 2016-07-06
CN105682742A (zh) 2016-06-15
WO2015031393A1 (en) 2015-03-05
AU2014311358A1 (en) 2016-04-07
EA201690323A1 (ru) 2016-07-29
US20170027930A1 (en) 2017-02-02
EP3038707A4 (en) 2017-03-01
KR20160047490A (ko) 2016-05-02
JP2016534121A (ja) 2016-11-04
US20150290124A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
US9486405B2 (en) Methods for the treatment of pediatric otic disorders
CA2723458C (en) Controlled release corticosteroid compositions and methods for the treatment of otic disorders
US8318817B2 (en) Controlled release antimicrobial compositions and methods for the treatment of otic disorders
AU2019275578B2 (en) Sterilization of ciprofloxacin composition
WO2010011466A2 (en) Controlled-release cns modulating compositions and methods for the treatment of otic disorders
MX2011000862A (es) Composiciones antimicrobianas de liberacion controlada y metodos para el tratamiento de trastornos oticos.
US20210393511A1 (en) Otic gel formulations for treating otitis externa
US20220233522A1 (en) Ciprofloxacin otic composition and kits and method for using same
GB2459910A (en) Sustained release corticosteroid compositions for treatment of otic disorders
US20180092911A1 (en) Otic gel formulations for treating otitis media

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190827